156 related articles for article (PubMed ID: 31357969)
1. Multiplex plasma protein profiling identifies novel markers to discriminate patients with adenocarcinoma of the lung.
Djureinovic D; Pontén V; Landelius P; Al Sayegh S; Kappert K; Kamali-Moghaddam M; Micke P; Ståhle E
BMC Cancer; 2019 Jul; 19(1):741. PubMed ID: 31357969
[TBL] [Abstract][Full Text] [Related]
2. Serum Cripto-1 is a novel biomarker for non-small cell lung cancer diagnosis and prognosis.
Xu CH; Wang Y; Qian LH; Yu LK; Zhang XW; Wang QB
Clin Respir J; 2017 Nov; 11(6):765-771. PubMed ID: 26605871
[TBL] [Abstract][Full Text] [Related]
3. Serological proteome analysis approach-based identification of ENO1 as a tumor-associated antigen and its autoantibody could enhance the sensitivity of CEA and CYFRA 21-1 in the detection of non-small cell lung cancer.
Dai L; Qu Y; Li J; Wang X; Wang K; Wang P; Jiang BH; Zhang J
Oncotarget; 2017 May; 8(22):36664-36673. PubMed ID: 28456790
[TBL] [Abstract][Full Text] [Related]
4. Performance of a multiplexed dual analyte immunoassay for the early detection of non-small cell lung cancer.
Doseeva V; Colpitts T; Gao G; Woodcock J; Knezevic V
J Transl Med; 2015 Feb; 13():55. PubMed ID: 25880432
[TBL] [Abstract][Full Text] [Related]
5. Serum Human Epididymis Secretory Protein 4 (HE4) is a Potential Prognostic Biomarker in Non-Small Cell Lung Cancer.
Mo D; He F
Clin Lab; 2018 Sep; 64(9):1421-1428. PubMed ID: 30274019
[TBL] [Abstract][Full Text] [Related]
6. Diagnostic Value of Serum miR-182, miR-183, miR-210, and miR-126 Levels in Patients with Early-Stage Non-Small Cell Lung Cancer.
Zhu W; Zhou K; Zha Y; Chen D; He J; Ma H; Liu X; Le H; Zhang Y
PLoS One; 2016; 11(4):e0153046. PubMed ID: 27093275
[TBL] [Abstract][Full Text] [Related]
7. Combined detection of estrogen and tumor markers is an important reference factor in the diagnosis and prognosis of lung cancer.
Bai Y; Shen W; Zhu M; Zhang L; Wei Y; Tang H; Zhao J
J Cell Biochem; 2019 Jan; 120(1):105-114. PubMed ID: 30216488
[TBL] [Abstract][Full Text] [Related]
8. Determination of 16 serum angiogenic factors in stage I non-small cell lung cancer using a bead-based multiplex immunoassay.
Klupczynska A; Dereziński P; Matysiak J; Dyszkiewicz W; Kasprzyk M; Kokot ZJ
Biomed Pharmacother; 2017 Apr; 88():1031-1037. PubMed ID: 28192876
[TBL] [Abstract][Full Text] [Related]
9. Potential circulating miRNA signature for early detection of NSCLC.
Arab A; Karimipoor M; Irani S; Kiani A; Zeinali S; Tafsiri E; Sheikhy K
Cancer Genet; 2017 Oct; 216-217():150-158. PubMed ID: 29025589
[TBL] [Abstract][Full Text] [Related]
10. Cyfra 21-1 as a biologic marker of non-small cell lung cancer. Evaluation of sensitivity, specificity, and prognostic role.
Wieskopf B; Demangeat C; Purohit A; Stenger R; Gries P; Kreisman H; Quoix E
Chest; 1995 Jul; 108(1):163-9. PubMed ID: 7541742
[TBL] [Abstract][Full Text] [Related]
11. Blood test shows high accuracy in detecting stage I non-small cell lung cancer.
Goebel C; Louden CL; Mckenna R; Onugha O; Wachtel A; Long T
BMC Cancer; 2020 Feb; 20(1):137. PubMed ID: 32085733
[TBL] [Abstract][Full Text] [Related]
12. Decreased expression of miR-204 in plasma is associated with a poor prognosis in patients with non-small cell lung cancer.
Guo W; Zhang Y; Zhang Y; Shi Y; Xi J; Fan H; Xu S
Int J Mol Med; 2015 Dec; 36(6):1720-6. PubMed ID: 26497897
[TBL] [Abstract][Full Text] [Related]
13. CYFRA 21-1 enzyme-linked immunosorbent assay. Evaluation as a tumor marker in non-small cell lung cancer.
Lai RS; Hsu HK; Lu JY; Ger LP; Lai NS
Chest; 1996 Apr; 109(4):995-1000. PubMed ID: 8635383
[TBL] [Abstract][Full Text] [Related]
14. Cell-free DNA levels in plasma of patients with non-small-cell lung cancer and inflammatory lung disease.
Szpechcinski A; Chorostowska-Wynimko J; Struniawski R; Kupis W; Rudzinski P; Langfort R; Puscinska E; Bielen P; Sliwinski P; Orlowski T
Br J Cancer; 2015 Jul; 113(3):476-83. PubMed ID: 26125447
[TBL] [Abstract][Full Text] [Related]
15. Proteomics analysis of human serum of patients with non-small-cell lung cancer reveals proteins as diagnostic biomarker candidates.
Boccellino M; Pinto F; Ieluzzi V; Giovane A; Quagliuolo L; Fariello C; Coppola M; Carlucci A; Santini M; Ferati K; Bexheti-Ferati A; Giordano A; Di Domenico M
J Cell Physiol; 2019 Dec; 234(12):23798-23806. PubMed ID: 31180588
[TBL] [Abstract][Full Text] [Related]
16. Diagnostic Value of Circulating CXC Chemokines in Non-small Cell Lung Cancer.
Spaks A; Jaunalksne I; Spaka I; Chudasama D; Pirtnieks A; Krievins D
Anticancer Res; 2015 Dec; 35(12):6979-83. PubMed ID: 26637925
[TBL] [Abstract][Full Text] [Related]
17. Serum biomarkers facilitate the recognition of early- stage cancer and may guide the selection of surgical candidates: a study of carcinoembryonic antigen and tissue polypeptide antigen in patients with operable non-small cell lung cancer.
Buccheri G; Ferrigno D
J Thorac Cardiovasc Surg; 2001 Nov; 122(5):891-9. PubMed ID: 11689793
[TBL] [Abstract][Full Text] [Related]
18. Diacetylspermine Is a Novel Prediagnostic Serum Biomarker for Non-Small-Cell Lung Cancer and Has Additive Performance With Pro-Surfactant Protein B.
Wikoff WR; Hanash S; DeFelice B; Miyamoto S; Barnett M; Zhao Y; Goodman G; Feng Z; Gandara D; Fiehn O; Taguchi A
J Clin Oncol; 2015 Nov; 33(33):3880-6. PubMed ID: 26282655
[TBL] [Abstract][Full Text] [Related]
19. [OLC1 protein levels in plasma of patients with non-small cell lung cancer and its clinical application].
Yang L; Xiao T; Tan J; Chen S; Gao Y; Cheng S; Liu X; Sun K
Zhonghua Zhong Liu Za Zhi; 2014 May; 36(5):362-5. PubMed ID: 25030592
[TBL] [Abstract][Full Text] [Related]
20. miR-1254 and miR-574-5p: serum-based microRNA biomarkers for early-stage non-small cell lung cancer.
Foss KM; Sima C; Ugolini D; Neri M; Allen KE; Weiss GJ
J Thorac Oncol; 2011 Mar; 6(3):482-8. PubMed ID: 21258252
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
